Vascular News and Research

RSS

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

Low levels of "good" cholesterol make it difficult to recover from stroke

People are at an increased risk of memory problems and greater disability after stroke if they have low levels of “good” cholesterol and high levels of homocysteine, an amino acid acquired mostly from eating meat.

27 Nov 2007

Isotechnika granted Norwegian patent for lead immunosuppressive drug

Isotechnika Inc. has announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247.

27 Nov 2007

Acute renal failure after non-cardiac operations

Patients undergoing major, non-cardiac surgery have a one percent risk of developing kidney failure, and those who do have kidney damage are at increased risk of death within a month after their operation.

26 Nov 2007

Vitamin E can significantly reduce risk of heart attacks for diabetics with certain gene variant

Vitamin E supplements can significantly reduce the risk of heart attacks and related deaths for diabetics who carry a particular version of a gene, according to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel.

21 Nov 2007

New study finds blood-spinal cord barrier compromised in mice with ALS

The blood-spinal cord barrier is functionally impaired in areas of motor neuron damage in mice modeling amyotrophic lateral sclerosis (ALS), report researchers at the University of South Florida Center for Aging and Brain Repair.

21 Nov 2007

How can we know early who will benefit from tumor target therapy?

The precise tailoring of tumor target treatment for patients with cancer is an unmet challenge.

21 Nov 2007

Measures that are needed to curb humanity's most fatal diseases

Several of the world's most eminent health scientists and organizations today publish a landmark global consensus on the 20 foremost measures needed to curb humanity's most fatal diseases, their study featured in Nature magazine.

21 Nov 2007

Threat women face from vascular disease not widely understood

Though arterial vascular disease is widespread and often deadly among older American women, doctors too often fail to spot and treat it, according to a new report by a team of vascular surgeons from the Columbia University Medical Center and Weill Cornell Medical College campuses of NewYork-Presbyterian Hospital.

21 Nov 2007

Project aims to deepen the medical and research community's understanding of women's health

Women's bodies and medical needs are vastly different than men's way beyond their reproductive systems.

20 Nov 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007

New device for screening potential new drug compounds

A new device invented by researchers at the University of Virginia could save pharmaceutical companies significant time and money in screening potential new drug compounds.

19 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

University of Delaware research to shed light on osteoporosis

Ten million people in the United States are estimated to already have bone diseases, and almost 34 million more are estimated to have low bone mass, putting them at increased risk for osteoporosis, according to the National Osteoporosis Foundation.

16 Nov 2007

Nitrite/nitrate-rich foods may help in heart attack survival

Nitrite/nitrate found in vegetables, cured meats and drinking water may help you survive a heart attack and recover quicker, according to a pre-clinical study led by a cardiovascular physiologist at The University of Texas Health Science Center at Houston.

13 Nov 2007

Life-threatening gene defect related to thoracic aortic disease discovered

A research team led by scientists at The University of Texas Medical School at Houston has identified a defective gene that affects vascular smooth-muscle cells in people who suffer from hereditary thoracic aortic disease, which can kill victims with little warning in the prime of their lives.

13 Nov 2007

Questions raised over the safety of the long-term use of the birth control pill

New research has again raised concerns about the safety of the long-term use of the birth control pill.

7 Nov 2007

New liver model for drug tests

In the early stages of drug development, a drug’s effect is tested in animal experiments.

6 Nov 2007

Your Apo E genotype plays part in likelihood of Alzheimer's and heart disease

We all carry the Apo E gene. It plays a key role in the development of Alzheimer's Disease and heart disease, along with a host of chronic ailments.

6 Nov 2007

Discovery of new hemoglobin function

A team of researchers from Wake Forest University, the National Institutes of Health and other institutions has discovered a previously undetected chemical process within the oxygen-carrying molecule hemoglobin that could have far-reaching implications for the treatment of cardiovascular diseases.

6 Nov 2007